
CTOR
Citius Oncology Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.720
Open
1.600
VWAP
1.59
Vol
579.13K
Mkt Cap
119.91M
Low
1.520
Amount
920.97K
EV/EBITDA(TTM)
--
Total Shares
78.37M
EV
123.71M
EV/OCF(TTM)
--
P/S(TTM)
--
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.
Show More
1 Analyst Rating

96.08% Upside
Wall Street analysts forecast CTOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTOR is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold

96.08% Upside
Current: 1.530

Low
3.00
Averages
3.00
High
3.00

96.08% Upside
Current: 1.530

Low
3.00
Averages
3.00
High
3.00
Maxim
Buy
to
Hold
downgrade
2025-05-23
Reason
Maxim
Price Target
2025-05-23
downgrade
Buy
to
Hold
Reason
Maxim downgraded Citius Oncology to Hold from Buy.
Maxim Group
Michael Okunewitch
Strong Buy
Initiates
$3
2024-11-27
Reason
Maxim Group
Michael Okunewitch
Price Target
$3
2024-11-27
Initiates
Strong Buy
Reason
Maxim initiated coverage of Citius Oncology with a Buy rating and $3 price target.
EF Hutton
Jason Kolbert
Strong Buy
Maintains
$6
2024-08-13
Reason
EF Hutton
Jason Kolbert
Price Target
$6
2024-08-13
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Citius Oncology Inc (CTOR.O) is -8.00, compared to its 5-year average forward P/E of -2.14. For a more detailed relative valuation and DCF analysis to assess Citius Oncology Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-2.14
Current PE
-8.00
Overvalued PE
1.89
Undervalued PE
-6.16
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
1.07
Current PS
3.28
Overvalued PS
3.04
Undervalued PS
-0.90
Financials
Annual
Quarterly
FY2025Q2
0.00
Total Revenue
FY2025Q2
YoY :
+1845.87%
-7.47M
Operating Profit
FY2025Q2
YoY :
-3164.05%
-7.74M
Net Income after Tax
FY2025Q2
YoY :
-375.00%
-0.11
EPS - Diluted
FY2025Q2
YoY :
-100.00%
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CTOR News & Events
Events Timeline
2025-07-15 (ET)
2025-07-15
08:36:27
Citius Oncology signs distribution agreement for Lymphir with Cencora

2025-07-14 (ET)
2025-07-14
08:38:19
Citius Oncology files to sell $15M of common stock, warrants

2025-06-17 (ET)
2025-06-17
08:10:20
Citius Oncology expects commercial launch of Lymphir in second half of 2025

Sign Up For More Events
Sign Up For More Events
News
8.5
07-17PRnewswireCitius Oncology Announces Closing of $9.0 Million Public Offering
8.5
07-16NewsfilterCitius Oncology Announces Pricing of $9.0 Million Public Offering
7.5
07-15NewsfilterCitius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
Sign Up For More News
People Also Watch

ALOT
AstroNova Inc
11.220
USD
-0.53%

ADVM
Adverum Biotechnologies Inc
2.770
USD
-2.46%

LTBR
Lightbridge Corp
15.070
USD
+1.21%

PAVS
Paranovus Entertainment Technology Ltd
0.840
USD
-3.45%

FSHP
Flag Ship Acquisition Corp
10.465
USD
-0.05%

DTSQ
DT Cloud Star Acquisition Corp
10.490
USD
+0.29%

HSPO
Horizon Space Acquisition I Corp
12.050
USD
-0.90%

MNOV
MediciNova Inc
1.230
USD
0.00%

INVE
Identiv Inc
3.400
USD
-4.76%

COYA
Coya Therapeutics Inc
5.810
USD
-2.52%
FAQ

What is Citius Oncology Inc (CTOR) stock price today?
The current price of CTOR is 1.53 USD — it has decreased -4.38 % in the last trading day.

What is Citius Oncology Inc (CTOR)'s business?

What is the price predicton of CTOR Stock?

What is Citius Oncology Inc (CTOR)'s revenue for the last quarter?

What is Citius Oncology Inc (CTOR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Citius Oncology Inc (CTOR)'s fundamentals?

How many employees does Citius Oncology Inc (CTOR). have?
